{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 120 of 122', '[1]', \"Anytime necessary to assess or follow up adverse events, at the subject's request, or per investigator decision. Perform procedures, spirometry, and\", 'laboratory tests as appropriate.', '[2]', 'Early discontinuation: For subject who discontinues observation early.', 'Exit: Approximately 18 months after randomization.', '[3]', 'Instruct subject and parent/caregiver to complete HRQOL questionnaires and bespoke questions at the start of the visit before other procedures (unless', 'specified otherwise). The same parent/caregiver should complete all relevant questionnaires during the study.', 'For age-relevant questionnaires, subject who transitions from one age group to the next age group during the study will complete the version first used.', '[4]', 'Parent/caregiver: EQ-5D-5L, EQ-5D-Y proxy (for subject aged 4-7 years); subject aged 8-12 years: EQ-5D-Y; subject aged 13-17 years: EQ-5D-5L.', 'In addition, instruct subject and parent/caregiver to complete the questionnaire as follows:', 'Before the OLFC.', 'When allergy symptoms due to food allergen exposure are reported to the study site and assessed as severe (Section 8.5.6.3), and 1 week later.', '[5]', 'For parent/caregiver.', '[6]', 'Parent/caregiver of subject aged < 12 years: FAQLQ-PF and FAIM-PF; parent/caregiver of subject aged 13-17 years: FAQLQ-PFT and FAIM-PFT;', 'subject aged 8-12 years: FAQLQ-CF and FAIM-CF; subject aged 13-17 years: FAQLQ-TF and FAIM-TF.', 'Instruct subject and parent/caregiver to complete the FAQLQ/FAIM before the OLFC.', '[7]', 'Day 1 of standard of care alone is the day of randomization, which must begin within 28 days after obtaining signed consent.', '[8]', 'For subject aged > 6 years, obtain PEFR at approximately the same time of day for each assessment visit (eg, morning, afternoon); record', 'the', 'best', 'result of 3 attempts. Obtain spirometry (FEV1) if PEFR shows a clinically relevant reduction, subject has clinical deterioration (eg, active wheeze on', 'physical examination), or as clinically indicated on unscheduled visits; record the best result of 3 attempts (if unable to successfully obtain, record', 'attempts and investigator assessment).', 'For subject aged 4-5 years, obtain PEFR; record results (if unable to successfully obtain, record attempts and investigator assessment).', '[9]', 'For subject with asthma. Evaluate asthma severity per NHLBI 2007 criteria (Table 19).', '[10]', 'Symptom-directed: Assess systems per standard of care at the study site or as clinically indicated by symptoms.', 'Complete: Assess systems (eg, general appearance, head, eyes, ears, nose, mouth, skin, heart, lungs, lymph nodes, gastrointestinal, genitourinary,', 'neurologic, and skeletal).', '[11] Instruct subject to avoid peanut during the study. Provide food/peanut allergy education (including recognition of an allergic reaction, symptoms of', 'anaphylaxis, administration of epinephrine auto-injector, anaphylaxis action plan, ways to minimize accidental exposure to peanut) per standard of care', 'at the study site.', '[12] Subject with unresolved adverse events at early discontinuation or study exit will have safety follow-up per Appendix 7.', '[13]', 'Review medications since previous visit. Instruct subject to discontinue antihistamines at least 5 half-lives of the medication before the OLFC.', \"Review the prescribing information to determine the half-life of each medication for the subject's relevant age group.\", '[14]', 'Perform before the OLFC.', '[15] Approximately 12 months (+1 month) after randomization. On the day after, phone subject for adverse event review.', '[16]', 'Refer to the laboratory manual for sample collection and processing.', '[17]', 'For all females of childbearing potential.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 121 of 122', 'ACT, Asthma Control Test; C-ACT, Childhood Asthma Control Test; disc, discontinuation; EQ-5D, European Quality of Life 5-Dimensions health', 'questionnaire; EQ-5D-5L, EQ-5D 5-Levels; EQ-5D-Y, EQ-5D Youth; FAIM, Food Allergy Independent Measure; FAIM-CF, FAIM - child form; FAIM-PF,', 'FAIM - parent form; FAIM-PFT, FAIM - parent form teenager; FAIM-TF, FAIM - teenager form; FAQL-PB, Food Allergy Quality of Life - Parental Burden;', 'FAQLQ, Food Allergy Quality of Life Questionnaire; FAQLQ-CF, FAQLQ - child form; FAQLQ-PF, FAQLQ - parent form; FAQLQ-PFT, FAQLQ - parent', 'form teenager; FAQLQ-TF, FAQLQ - teenager form; FEV1, forced expiratory volume in in the first second of expiration; HADS, Hospital Anxiety and', 'Depression Scale; HRQOL, health-related quality of life; na, not applicable; NHLBI, National Heart, Lung, and Blood Institute; OLFC, open-label food', 'challenge; PEFR, peak expiratory flow rate; SCORAD, scoring atopic dermatitis; TNSS, Total Nasal Symptom Score; unsched, unscheduled.']\n\n###\n\n", "completion": "END"}